Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS).

Francesco Salton Paola ConfalonieriStefano CentanniMichele MondoniNicola PetrosilloPaolo BonfantiGiuseppe LapadulaDonato LacedoniaAntonio VozaNicoletta CarpenèMarcella MonticoNicolò ReccardiniGianfranco Umberto MeduriBarbara Ruaronull nullMarco Confalonieri

Published in: The European respiratory journal (2022)

Prolonged, higher dose methylprednisolone did not reduce mortality at 28 days compared to conventional dexamethasone in COVID-19 pneumonia.

Keyphrases

high dose
coronavirus disease
sars cov
low dose
cardiovascular events
respiratory syndrome coronavirus
respiratory failure
risk factors
cardiovascular disease
type diabetes
intensive care unit